Three Big Obstacles Bay Area's Raptor Needs to Overcome

The latest earnings report from Raptor Pharmaceuticals (NASDAQ: RPTP) was full of good news. Quarterly sales of its lead product, Procysbi, were higher than ever, and heading higher. Recently it purchased an antibiotic that had already won approval in the EU and is likely to receive an expedited review from the FDA.

Despite this great news, the stock is down over 22% this year. Although it's bounced around since the Feb. 25 release of fourth-quarter earnings, the stock has remained flat. In the face of all the good news, you'd expect some positive movement. Let's take a closer look at the three biggest challenges this company is facing. Maybe then we'll be able to understand why the stock price and news flow aren't lining up.

Back to news